Laxmi N. Buddharaju
Expertise in
9
conditions

Dr. Laxmi N. Buddharaju

Hematology | Oncology
411 Laurel Street, Suite 3300, 
Des Moines, IA 
Accepting New Patients
Offers Telehealth
Expertise in
9
conditions
411 Laurel Street, Suite 3300, 
Des Moines, IA 

Overview

Lasmi Narayana R. Buddharaju, MD, is board-certified in hematology and oncology at MercyOne Des Moines Hematology Oncology. He is also the statewide medical director for MercyOne Cancer Care, providing leadership and strategic direction for colleagues and patients.He treats all cancer types and is fully committed to walking beside you through every step of your cancer journey. He takes the time to listen to you, understand your goals and concerns and makes sure you're informed and supported.Dr. Buddharaju’s practice is grounded in compassion, clear communication and personalized care tailored to your needs.

Dr. Buddharaju is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC).

Dr. Buddharaju is board certified in Hematology Oncology, American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 4 clinical trials. Dr. Buddharaju is currently accepting new patients.

Graduate Institution

Long Island University, Brooklyn, New York, Biochemistry - 1992

Residency

University of New York Hospital, Buffalo, New York - 1996

Specialties

Hematology
Oncology

Licenses

Internal Medicine in IA

Board Certifications

Hematology Oncology, American Board Of Internal Medicine

Fellowships

University of Maryland, Baltimore, Maryland - 2001

Hospital Affiliations

Perkins County Health Services
Chase County Community Hospital
Great Plains Health
Mercyone Des Moines Medical Center
Gothenburg Health

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 8 Less Insurance Carriers -

Locations

MercyOne Richard Deming Cancer Center Des Moines Hematology Oncology
411 Laurel Street, Suite 3300, Des Moines, IA 50313
Other Locations
Mercyone Richard Deming Cancer Center
411 Laurel St, Ste 3300, Des Moines, IA 50314

Additional Areas of Focus

Dr. Buddharaju has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cabozantinib S-malate, Docetaxel, Gemcitabine Hydrochloride, Nab-paclitaxel, Nivolumab, Paclitaxel, Ramucirumab
Study Phase: Phase 2
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2026
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Talazoparib
Study Phase: Phase 2
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: March 04, 2026
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 3
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Other, Drug
Study Drugs: Pembrolizumab, Pemetrexed, Carboplatin
Study Phase: Phase 2
View 3 Less Clinical Trials

3 Total Publications

Immunotherapy in lung cancer: the chemotherapy conundrum.
Immunotherapy in lung cancer: the chemotherapy conundrum.
Journal: Chinese clinical oncology
Published: December 16, 2019
Similar Doctors
Expertise in
103
conditions
Dr. Tara Graff
Hematology | Oncology
Expertise in
103
conditions
Dr. Tara Graff
Hematology | Oncology
Referral may be required

Mission Blood + Cancer

411 Laurel St., Suite A300, 
Des Moines, IA 
 (3.9 miles away)
515-247-3970
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tara Graff, DO, specializes in Hematology/Oncology at Mission Blood + Cancer in Des Moines, Iowa.Medical interests:Dr. Graff has led several clinical research projects and has published many original oncology and hematology articles.Certifications: Internal Medicine; Medical OncologyMedical School: Lake Erie College of Osteopathic Medicine, Bradenton, FL Residency:Medical College of Wisconsin; Froedtert Memorial Lutheran Hospital Fellowship: Medical College of Wisconsin; Froedtert Memorial Lutheran Hospital. Dr. Graff is highly rated in 103 conditions, according to our data. Her clinical expertise encompasses B-Cell Lymphoma, Non-Hodgkin Lymphoma, Plasmacytoma, Paget Disease of the Breast, and Bone Marrow Aspiration. Dr. Graff is currently accepting new patients.

Expertise in
105
conditions
Dr. Thomas Buroker
Hematology | Oncology
Expertise in
105
conditions
Dr. Thomas Buroker
Hematology | Oncology
Referral may be required

John Stoddard Cancer Center

1200 Pleasant St, 
Des Moines, IA 
 (4.6 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Dr. Thomas Buroker completed his undergraduate work at The University of Iowa where he graduated in 1964. He went on to graduate from the College of Osteopathy Medical and Surgery (now the Des Moines University). Dr. Buroker completed a residency at the Grace Hospital in Detroit. He completed a fellowship in Medical Oncology at Wayne State University Medical School in Detroit. Dr. Buroker is highly rated in 105 conditions, according to our data. His clinical expertise encompasses Severe Congenital Neutropenia, Lung Cancer, Pleuropulmonary Blastoma, Bone Marrow Aspiration, and Gastrostomy. Dr. Buroker is currently accepting new patients.

Expertise in
88
conditions
Dr. Angela Sandre
Hematology | Oncology
Expertise in
88
conditions
Dr. Angela Sandre
Hematology | Oncology
Referral may be required

Mission Blood + Cancer

411 Laurel St., Suite A300, 
Des Moines, IA 
 (3.9 miles away)
515-247-3970
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Angela Sandre, DO is a medical oncology and hematology physician with Mission Cancer + Blood. Dr. Sandre earned her medical degree from Des Moines University. Dr. Sandre completed both her internship and residency at the University of Iowa, Des Moines Internal Medicine Residency. Following residency, Dr. Sandre completed a fellowship at the Huntsman Cancer Institute at the University of Utah in Salt Lake City. Dr. Sandre is highly rated in 88 conditions, according to our data. Her clinical expertise encompasses B-Cell Lymphoma, Paget Disease of the Breast, Non-Hodgkin Lymphoma, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Sandre is currently accepting new patients.

Frequently Asked Questions about Dr. Laxmi N. Buddharaju

How do I make an appointment with Dr. Laxmi N. Buddharaju?

You can book an appointment with Dr. Laxmi N. Buddharaju by calling their office at 515-643-8735. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Laxmi N. Buddharaju a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Laxmi N. Buddharaju is classified as an Advanced expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Laxmi N. Buddharaju specialize in?

While Dr. Laxmi N. Buddharaju is a Hematology, they have specific expertise in Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Lung Adenocarcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Laxmi N. Buddharaju participate in research or clinical trials?

Yes. Dr. Laxmi N. Buddharaju has published 3 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Dr. Laxmi N. Buddharaju's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Laxmi N. Buddharaju accept my insurance?

Dr. Laxmi N. Buddharaju accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 515-643-8735 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Buddharaju's expertise for a condition
ConditionClose
      View All 9 Advanced Conditions
      View All 41 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile